Natera, Inc. (NASDAQ:NTRA) Shares Acquired by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP increased its stake in Natera, Inc. by 30% during the first quarter, now holding a total of $1.31 million in shares.
• Directors of Natera sold significant amounts of stock, with Gail Boxer Marcus selling 4,299 shares for about $719,480, indicating a 34.62% decrease in their ownership.
• Despite recent insider selling, Natera reported strong quarterly earnings with revenue of $501.83 million, surpassing analyst estimates by a notable margin.

GSA Capital Partners LLP boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,244 shares of the medical research company's stock after purchasing an additional 2,133 shares during the period. GSA Capital Partners LLP's holdings in Natera were worth $1,307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. HighPoint Advisor Group LLC boosted its stake in shares of Natera by 30.8% during the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after purchasing an additional 468 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after purchasing an additional 740 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares in the last quarter. Teza Capital Management LLC bought a new position in shares of Natera during the fourth quarter valued at approximately $221,000. Finally, Asset Management One Co. Ltd. bought a new position in shares of Natera during the first quarter valued at approximately $6,753,000. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 6,092 shares of Natera stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $851,722.52. Following the completion of the transaction, the chief executive officer directly owned 169,400 shares of the company's stock, valued at $23,683,814. The trade was a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 2,206 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $308,420.86. Following the sale, the insider directly owned 126,059 shares in the company, valued at $17,624,308.79. This represents a 1.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,936 shares of company stock worth $7,483,846 over the last quarter. 7.60% of the stock is owned by corporate insiders.

Natera Trading Up 0.7%

NTRA traded up $0.92 on Friday, hitting $134.58. The company had a trading volume of 1,165,817 shares, compared to its average volume of 1,202,365. The firm has a market cap of $18.38 billion, a P/E ratio of -91.55 and a beta of 1.76. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The company's fifty day moving average price is $157.16 and its 200 day moving average price is $155.88.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. Natera's revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.56) EPS. On average, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. UBS Group upped their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Finally, Piper Sandler lifted their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average target price of $183.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.